AtriCure's (NASDAQ:ATRC) AtriClip, OUS, Restructing Key Catalysts in 2011

AtriCure Inc. (NASDAQ:ATRC) has several catalysts which could drive the company in 2011, including AtriClip, OUS sales, and the restructuring of its sales territories.

Canaccord noted, "Following our attendance at Boston AF 2011 and meeting with management, we reiterate our BUY rating and increase our price target. We remain bullish on the AtriClip opportunity, and think it will also pull through higher sales of ATRC’s US Open Heart product line, which we also think will benefit from the company’s recent sales territory restructuring. We are also confident ATRC can grow OUS sales at a double-digit rate, augmented by upcoming product launches."

Canaccord Genuity maintains a "Buy" rating on AtriCure Inc. (ATRC), which closed Tuesday at $10.97, down $0.16, or 1.44 percent. Canaccord raised their price target on AtriCure from $10.75 to $13.50.